• Kai Wang, Ling-Ling Zhuang, Hai-Lan Shen, Rui-De Su, Zhen-Yu Luo, and Wen-Rong Wang.
• Department of Family Planning, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
• Medicine (Baltimore). 2023 Apr 7; 102 (14): e33532e33532.

AbstractTo analyze the efficacy and influencing factors of Mifepristone combined with estrogen-progesterone sequential therapy (Femoston) in the treatment of incomplete abortion. This retrospective cohort study included 93 patients with incomplete abortion. All patients took 50 mg of Mifepristone 2 times a day for 5 days and then took Femoston once a day (starting with estradiol tablets/2 mg) for 28 days. Without any indication of intrauterine residue by ultrasonic examination was judged to be effective. According to statistical analysis, this study calculated the effective rate and analyzed its influencing factors. A 2-sided value of P < .05 was considered statistically significant. The total response rate of the treatment regimen was 86.67%. body mass index was a significant influencing factor for treatment outcome (OR 0.818, 95% confidence interval 0.668-0.991, P = .041). For patients with incomplete abortion, Mifepristone combined with estrogen-progesterone sequential therapy has a remarkable therapeutic effect. Patients with a lower body mass index may respond much more significantly to this treatment regimen.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

23 keywords...

hide…